Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology

Chemotherapy, radiotherapy, targeted therapy, and immunotherapy have brought hope to cancer patients. With the prolongation of survival of cancer patients and increased clinical experience, cancer-therapy-induced cardiovascular toxicity has attracted attention. The adverse effects of cancer therapy...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of molecular sciences Vol. 23; no. 18; p. 10617
Main Authors Liang, Zehua, He, Yuquan, Hu, Xin
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 13.09.2022
MDPI
Subjects
Breast cancer
Cancer
Cancer therapies
Cardiac arrhythmia
cardio-oncology
Cardiology
Cardiomyocytes
Cardiomyopathy
cardioprotection
Cardiotoxicity
Cardiovascular disease
Cardiovascular diseases
cardiovascular toxicity
Chemotherapy
DNA damage
Drug dosages
Drugs
Health services
Heart
Immunotherapy
Medical prognosis
Medical research
Mitochondria
Molecular biology
Morbidity
Mortality
Myocarditis
Oncology
Oxidative stress
Patients
Prolongation
Radiation therapy
reverse cardio-oncology
Review
Toxicity
traditional Chinese medicine
Online AccessGet full text

Cover

More Information
Summary:Chemotherapy, radiotherapy, targeted therapy, and immunotherapy have brought hope to cancer patients. With the prolongation of survival of cancer patients and increased clinical experience, cancer-therapy-induced cardiovascular toxicity has attracted attention. The adverse effects of cancer therapy that can lead to life-threatening or induce long-term morbidity require rational approaches to prevention and treatment, which requires deeper understanding of the molecular biology underpinning the disease. In addition to the drugs used widely for cardio-protection, traditional Chinese medicine (TCM) formulations are also efficacious and can be expected to achieve “personalized treatment” from multiple perspectives. Moreover, the increased prevalence of cancer in patients with cardiovascular disease has spurred the development of “reverse cardio-oncology”, which underscores the urgency of collaboration between cardiologists and oncologists. This review summarizes the mechanisms by which cancer therapy induces cardiovascular toxicity, the combination of antineoplastic and cardioprotective drugs, and recent advances in reverse cardio-oncology.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms231810617